Cancer biotech Cerulean files for a $75 million IPO

By: Renaissance Capital

Posted: 3/10/2014 9:10:00 AM

Referenced Stocks: CERU

Cerulean Pharma, a clinical-stage biotech developing targeted
cancer therapies for liver and ovarian cancer, filed on Monday
with the SEC to raise up to $75 million in an initial public
offering. The Cambridge, MA-based company, which was founded in
2005, plans to list on the NASDAQ under the symbol CERU. Cerulean
initially filed confidentially on January 30, 2014. Leerink
Partners is the sole bookrunner on the deal. No pricing terms
were disclosed.